


FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT 	ATTY DOCKET NO.	SERIAL NO.
	BEH-7354 -DIV	09/542,445
	APPLICANT(S) Staples, et al.	
FILING DATE April 4, 2000		GROUP NO. 1645

UNITED STATES PATENT DOCUMENTS

EXAM. INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
SD	AA	5,185,243	02/09/93	Ullman et al.	435	6	/
	AB	5,089,390	02/18/92	Davalian et al.	435	7.93	
	AC	4,959,303	09/25/90	Milburn et al.	435	7	
	AD	4,868,104	09/19/89	Kurn et al.	435	6	
	AE	4,857,453	08/15/89	Ullman et al.	435	7	
SD	AF	4,486,530	12/04/84	David et al.	435	7	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES/NO
SD	BA	WO 83/00147	01/20/83	PCT			
SD	BB	WO96/02004		PCT			

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)


SD	CA	Broughton and Strong, Clin. Chem. 22:726-732 (1976)
	CB	Butler, <i>J. Immunol Meth</i> 7:1-24 (1975)
	CC	Carey, "Organic Chemistry," McGraw Hill Inc., New York, New York, First edition, 1987, pages 994-995 and 609.
	CD	Cuatrecasas, <i>J. Biol. Chem.</i> , 245:3059 (1970)
	CE	Epinette, et al., <i>Journal of the American Academy of Dermatology</i> 17(6):1962-71 (1987)
	CF	Galfre, et al., (1981) Preparation of Monoclonal Antibodies: Strategies and Procedures, <i>Methods Enzymol</i> , 73:3-46
	CG	Grabarek, et al., (1990) Zero-length Crosslinking Procedure With The Use of Active Esters, <i>Anal. Biochem.</i> 185: 131-135
	CH	Heathcock, et al., "Introduction to Organic Chemistry," MacMillan Publishing Company, New York, New York, Third edition, 1985, pages 814 and 493
SD	CI	Kohler and Milstein, <i>Nature</i> 256:495-497, 1975

EXAMINER:

SD

DATE:

Aug 01

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT 	ATTY DOCKET NO.	SERIAL NO.
	BEH-7354 - DIV	09/542,445
	APPLICANT(S) Staples, et al.	
FILING DATE April 4, 2000		GROUP NO. 1645

UNITED STATES PATENT DOCUMENTS

EXAM. INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
SD	AG	4,318,980	03/09/82	Boguslaski et al.	435	7	
	AH	4,275,149	06/23/81	Litman et al.	435	7	
	AI	4,233,402	11/11/80	Maggio et al.	435	7	
	AJ	3,996,345	12/07/76	Ullman et al.	424	12	
	AK	3,817,837	06/18/74	Rubenstein et al.	195	103.5	
	AL	4,454,232	06/12/84	Breglio et al.	436	504	
	AM	4,110,076	08/29/78	Margherita	23	230.6	
SD	AN	4,052,504	10/04/77	Hertl et al.	424	1	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES/NO
SD	BC	0 392 332		EPO			NO
SD	BD	0 218 309		EPO			
SD	BE	0 165 699		EPO (Abstract)			

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)


SD	CJ	Langman, et al., <i>Therapeutic Drug Monitoring</i> (1994) 16:602-607					
SD	CK	Lee, et al., <i>Pharmaceutical Research</i> 7 (2):161-166 (1990)					
SD	CL	Lymphocyte Hybridomas, ed. Melchers, et al. Springer-Verlag (New York 1978)					
SD	CM	Nature 266:495 (1977)					
	CN	Nelson, et al. <i>Journal of Medicinal Chemistry</i> 33 (2) :833-838 (1990)					
	CO	Nerli, et al. <i>Arch Int Physiol Biochim Biophys</i> (1994) 102 (1):5-8					
	CP	Playfair, et al. <i>Br. Med. Bull</i> , 30:24-31 (1974)					
	CQ	Science 208:693 (1980)					
SD	CR	Seth et al., <i>Clin Chem.</i> (1975) 21(10): 1406-1413					

EXAMINER:

SD

DATE:

Aug 01

FORM PTO-1449	ATTY DOCKET NO.	SERIAL NO.
INFORMATION DISCLOSURE STATEMENT	BEH-7354 - DIV	09/542,445
	APPLICANT(S)	Staples, et al.
	FILING DATE	April 4, 2000
		GROUP NO. 1645

UNITED STATES PATENT DOCUMENTS

EXAM. INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES/NO
SD	BF	0 155 104	EPO (Abstract)			
SD	BG	0 100 543	EPO			
SD	BH	2,014,233	Canada			

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

SD	CS	Shaw, et al. <i>Therapeutic Drug Monitoring</i> , (1995) 17:690-699				
	CT	Wu, <i>Perspective in Drug Discovery and Design</i> , (1994) 2:185-204				
	CU	Yalow, et al., <i>J. Clin. Invest</i> , 39:1157 (1960)				
	CV	Tsina, I., et al., High-performance liquid chromatographic method for the determination of mycophenolate mofetil in human plasma, <i>Journal of Chromatography B</i> , 681 (1996) 347-353				
	CW	Haley, C.J., et al., Analytical Performance of an Emit Assay for Mycophenolic Acid in Plasma, <i>Clinical Chemistry</i> , Vol. 43, No. 6, 1997, Abstract No. 474				
	CX	Allison A., et al., Mechanisms of Action of Mycophenolic Acid, <i>Annals of the New York Academy of Sciences</i> , Vol. 696, pp. 63-87, 1993				
	CY	Holt, D.W., et al., Monitoring New Immunosuppressive Agents, Are the Methods Adequate?, <i>Drug Metabolism and Drug Interactions</i> , Vol. 14, No. 1, 1992				
	CZ	Yatscoff, R.W., et al, Pharmacodynamic Monitoring of Immunosuppressive Drugs, <i>Transplantation Proceedings</i> , Vol. 28, No. 6 (December) 1996: pp 3013-3015				
	CCA	Loralie J. Langman et al., "Blood Distribution of Mycophenolic Acid," <i>Therapeutic Drug Monitoring: A Journal Devoted To Therapeutic Drug Monitoring and Clinical Drug Toxicology</i> , Vol. 16, No. 6, December 1994, pages 602-607				
SD	CCB	Irene Nowak et al., "Mycophenolic Acid Binding to Human Serum Albumin: Characterization and Relation to Pharmacodynamics," <i>Clinical Chemistry</i> , Vol. 41, No. 7, 1995, pages 1011-1017.				

EXAMINER: SD	DATE: Aug 01
--------------	--------------